Patients and transplantation characteristics
| Characteristic . | All (n = 47) . | Mutated BCR-ABL1 (n = 19) . | Nonmutated BCR-ABL1 (n = 28) . | P . |
|---|---|---|---|---|
| Median age, y (range) | 44 (19-64) | 46 (19-63) | 43 (22-64) | .87 |
| Male sex, % | 27 (57) | 12 (63) | 15 (54) | .56 |
| Previous IFN-α, % | 14 (30) | 7 (37) | 7 (25) | .51 |
| Median time on imatinib, mo (range) | 15 (1-57) | 12 (1-49) | 18 (3-57) | .16 |
| Best response to imatinib | .53 | |||
| CHR, % | 20 (43) | 10 (53) | 10 (36) | |
| MCyR, % | 17 (36) | 6 (32) | 11 (39) | |
| CCyR, % | 15 (32) | 5 (26) | 10 (36) | |
| Reason for TKI failure, % | .07 | |||
| Intolerance | 1 (2) | 1 (5) | 0 (0) | |
| Hematologic resistance | 2 (4) | 1 (5) | 1 (4) | |
| Loss of CHR | 7 (15) | 3 (16) | 4 (14) | |
| Cytogenetic resistance | 6 (13) | 0 (0) | 6 (21) | |
| Loss of cytogenetic response | 8 (17) | 1 (5) | 7 (26) | |
| Transformation to AP | 7 (15) | 3 (16) | 4 (14) | |
| Transformation to BP | 16 (34) | 10 (53) | 6 (21) | |
| Received second TKI, % | 29 (62) | 16 (84) | 13 (46) | .01 |
| Nilotinib, % | 13 (28) | 8 (42) | 5 (18) | |
| Dasatinib, % | 13 (28) | 7 (37) | 6 (21) | |
| Bosutinib, % | 3 (6) | 1 (5) | 2 (7) | |
| Best response to second TKI | .91 | |||
| CHR, % | 4 (14) | 3 (18) | 1 (8) | |
| MCyR, % | 8 (28) | 5 (31) | 3 (23) | |
| CCyR, % | 6 (21) | 4 (25) | 2 (15) | |
| Received third TKI, % | 4 (8.5) | 2 (11) | 2 (7) | > .999 |
| Median time from diagnosis to HSCT, mo (range) | 25 (6-168) | 24 (6-114) | 28 (6-168) | .39 |
| Stage at HSCT | .18 | |||
| First CP, % | 16 (34) | 4 (21) | 12 (43) | |
| AP, % | 12 (26) | 4 (21) | 8 (28) | |
| BP, % | 9 (19) | 6 (32) | 3 (11) | |
| Second CP, % | 10 (21) | 5 (26) | 5 (18) | |
| Matched-related HSCT, % | 23 (49) | 11 (58) | 12 (43) | .67 |
| RIC regimen, % | 32 (68) | 10 (53) | 22 (78) | .10 |
| Characteristic . | All (n = 47) . | Mutated BCR-ABL1 (n = 19) . | Nonmutated BCR-ABL1 (n = 28) . | P . |
|---|---|---|---|---|
| Median age, y (range) | 44 (19-64) | 46 (19-63) | 43 (22-64) | .87 |
| Male sex, % | 27 (57) | 12 (63) | 15 (54) | .56 |
| Previous IFN-α, % | 14 (30) | 7 (37) | 7 (25) | .51 |
| Median time on imatinib, mo (range) | 15 (1-57) | 12 (1-49) | 18 (3-57) | .16 |
| Best response to imatinib | .53 | |||
| CHR, % | 20 (43) | 10 (53) | 10 (36) | |
| MCyR, % | 17 (36) | 6 (32) | 11 (39) | |
| CCyR, % | 15 (32) | 5 (26) | 10 (36) | |
| Reason for TKI failure, % | .07 | |||
| Intolerance | 1 (2) | 1 (5) | 0 (0) | |
| Hematologic resistance | 2 (4) | 1 (5) | 1 (4) | |
| Loss of CHR | 7 (15) | 3 (16) | 4 (14) | |
| Cytogenetic resistance | 6 (13) | 0 (0) | 6 (21) | |
| Loss of cytogenetic response | 8 (17) | 1 (5) | 7 (26) | |
| Transformation to AP | 7 (15) | 3 (16) | 4 (14) | |
| Transformation to BP | 16 (34) | 10 (53) | 6 (21) | |
| Received second TKI, % | 29 (62) | 16 (84) | 13 (46) | .01 |
| Nilotinib, % | 13 (28) | 8 (42) | 5 (18) | |
| Dasatinib, % | 13 (28) | 7 (37) | 6 (21) | |
| Bosutinib, % | 3 (6) | 1 (5) | 2 (7) | |
| Best response to second TKI | .91 | |||
| CHR, % | 4 (14) | 3 (18) | 1 (8) | |
| MCyR, % | 8 (28) | 5 (31) | 3 (23) | |
| CCyR, % | 6 (21) | 4 (25) | 2 (15) | |
| Received third TKI, % | 4 (8.5) | 2 (11) | 2 (7) | > .999 |
| Median time from diagnosis to HSCT, mo (range) | 25 (6-168) | 24 (6-114) | 28 (6-168) | .39 |
| Stage at HSCT | .18 | |||
| First CP, % | 16 (34) | 4 (21) | 12 (43) | |
| AP, % | 12 (26) | 4 (21) | 8 (28) | |
| BP, % | 9 (19) | 6 (32) | 3 (11) | |
| Second CP, % | 10 (21) | 5 (26) | 5 (18) | |
| Matched-related HSCT, % | 23 (49) | 11 (58) | 12 (43) | .67 |
| RIC regimen, % | 32 (68) | 10 (53) | 22 (78) | .10 |
IFN indicates interferon-α.